Filing Flows › Health Care › Puma Biotechnology (PBYI)
Puma Biotechnology (PBYI) earnings and revenue breakdown
Latest: Q3 2026 · 8-K filed Nov 5, 2026
Q3 2026 Revenue up 1% year over year to $55.1M · 11¢ of every $1 of revenue kept as net profit · operating margin 9.6%
Puma Biotechnology made $55.1M in Q3 2026 (+1% Y/Y): Product revenue, net $54.1M, Royalty revenue $1.0M. Operating margin 9.6%, net earnings $6.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 8-K filed Nov 5, 2026 (preliminary, from the earnings release).
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $55.1M in Q3 2026, up 1% year over year and down 2% from the previous quarter. Product revenue, net was the largest line at 98% of revenue. Product revenue, net added $2.2M year over year (up 4%), 352% of the total change. Royalty revenue declined 62%.
Operating profit was $5.3M, a 9.6% margin (down 8.0 points year over year). Operating profit fell $4.3M even though revenue rose $625K versus Q3 2025, so costs grew faster than sales. Total costs grew 11% against revenue growth of 1%. The fastest-growing cost line was Cost of revenue (+25%). Net earnings were $6.0M, down 32% year over year. The effective tax rate was 3.2%.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 8-K | Nov 5, 2026 | $55.1M | +1% | 9.6% | $6.0M | — |
| Q2 2026 | 10-Q | Aug 6, 2026 | $56.5M | +8% | 13.4% | $8.2M | $1.6M |
| Q1 2026 | 10-Q | May 7, 2026 | $44.8M | -3% | -8.5% | −$3.8M | $15.4M |
| Q4 2025 | 10-K | Feb 26, 2026 | $75.5M | +28% | 22.7% | $13.4M | $14.4M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $54.5M | -32% | 17.6% | $8.8M | $9.7M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $52.4M | +11% | 12.7% | $5.9M | $14.1M |
| Q1 2025 | 10-Q | May 8, 2025 | $46.0M | +5% | 8.7% | $3.0M | $3.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
In its own words, from its 8-K, filed Aug 6, 2026.
Puma Biotechnology against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +1% against the peers' median +7%. Operating margin: 9.6% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| PBYI Puma Biotechnology | Q3 2026 | $55.1M | +1% | 9.6% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Puma Biotechnology 8-K on SEC EDGAR · CIK 1401667 · Pharmaceutical Preparations
13F: who owns PBYI and who is buying
More on PBYI
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results